The long-acting version of the diabetes drug Byetta from Amylin Pharmaceuticals, Bydureon (exenatide extended release), has been approved by the U.S. Food and Drug Administration.
The once-weekly injection would include a label warning that the drug caused specific thyroid tumors in rats, the Dow Jones news service reported. It is not known whether Bydureon causes such tumors in people, the label warning says but it should not be used by people with a family history of medullary thyroid carcinoma (a form of cancer), the warning continues.
The FDA declined approval of Bydureon twice in 2010 requesting additional studies and clinical information, Dow Jones reported.
Bydureon is a “glucagon-like peptide-1 (GLP-1) receptor,” a class of medications that helps the body produce more insulin, which helps regulate blood sugar.
Random Posts
Tags: blood sugar, Bydureon, Byetta, diabetes drug
